Categories
Cardiovascular
Diagnostics
Endocrinology
Health Insurance
Medical Devices
Mental Health
Nutrition
Oncology
Public Health
Sexual Health
Popular Articles
Benefits Of Grapefruit

About 0.59% Of Vietnamese Fishery Workers Are HIV-Positive, Prevalence Could Rise By 2013, Survey Says
An estimated 33,000 of the total 5.5 million workers in Vietnam"s fishery sector, or about 0.59%, were living with HIV in 2008, according to a survey released Tuesday by Vietnam"s fishery program, VNA/VOV News reports (VNA/VOV News, 5/27). The report also predicted that the number of HIV-positive people in Vietnam"s fishery sector could rise to 58,000 by 2013. According to a second survey, conducted simultaneously, a lack of knowledge about the disease has contributed to the fishery sector"s relatively high HIV prevalence. Vietnam"s Ministry of Agriculture and Rural Development as part of its Strengthening of Fisheries Administration conducted the survey with support from the Danish International Development Agency.For the first survey, researchers selected five provinces that were geographically and occupationally representative of the fishery industry. They surveyed 2,350 volunteers from four fishery trades: exploitation, processing, cultivation and provision. Fourteen of the survey participants disclosed that they had tested positive for HIV. Researchers then applied the Means of Transmission Model to estimate that about 0.59% of the country"s fishery workers are HIV-positive. Do Thanh Nam, who led the survey, said the industry"s "alarming" HIV rates are "caused by a lack of attention on HIV/AIDS risk among fishery workers" (VietNamNet Bridge, 5/27). Do also said that the survey might provide only a "snapshot" of the sector"s HIV prevalence (VNA/VOV News, 5/27).For the second survey, STOFA researchers surveyed 3,400 participants from nine provinces and found that many lacked sufficient knowledge about HIV. About 14.4% of survey respondents mistakenly believed HIV could be transmitted through mosquitoes or sharing tools; about 6.4% believed that hugging or kissing could transmit the virus; and about 15.8% believed having unprotected sex with commercial sex workers carried no risk of contracting HIV. In addition, 17.3% of male fishery workers reported using condoms with commercial sex workers. Le Thi Mong Phuong, who led the second survey, said that fishery workers often receive inadequate and unsystematic information about the disease. "Most of them learn about HIV/AIDS from television or radio, but rarely and irregularly," she said. Furthermore, many fishery workers reported spending long periods of time away from home, with 67% of 817 workers reporting absences of more than seven months per year and 21% reporting absences of four to six months per year.Vu Van Tam, deputy minister for agriculture and rural development, said that his ministry will use the results of the survey to develop HIV prevention and control strategies for the industry. Peter Lysholt Hansen, Danish ambassador to Vietnam, added that HIV/AIDS could jeopardize the recent growth in Vietnam"s agricultural sector because the disease poses high treatment costs for families, as well as costs from a weakened labor force. The surveys recommended that Vietnam address HIV/AIDS among fishery workers by strengthening a communications campaign and launching a program to provide condoms for high-risk groups (VietNamNet Bridge, 5/27).
generic viagra online
Alzheimer's Disease Is The Focus Of TBSI Annual Neuroscience Symposium
Brazos Valley residents, neuroscience researchers, and interested clinicians will each have opportunities to hear from internationally recognized researchers on the topic of aging and Alzheimer"s Disease during the Texas Brain and Spine Institute"s Third Annual Neuroscience Symposium on September 3 and 4. This year"s symposium will consist of an evening of public presentations aimed at helping local residents, Alzheimer"s patients, and their family members better understand early signs of the disease and ways to reduce your risk. The Friday afternoon session will feature a clinical presentation for health providers and researchers.
News of the day
Medicare Expenditures Decrease For Glaucoma Surgery As Number Of Procedures Increases
The overall number of glaucoma surgical procedures appears to be increasing, but payments by Medicare for the procedures have been decreasing, according to a report in the July issue of Archives of Ophthalmology, one of the JAMA/Archives journals.
Health Insurance

CEL-SCI To Present Data From Multikine Clinical Trials At National Institutes Of Health (NIH), National Cancer Institute (NCI) Seminar Series

CEL-SCI Corporation (NYSE Amex: CVM), a late stage cancer immunotherapy company, announced that Dr. Eyal Talor, CEL-SCI"s Senior Vice President of Research and Manufacturing, has been invited to present to the NIH, NCI"s Clinical Center and the Center for Human Immunology, NERD (New Research and Development) Seminar Series, which will take place on Friday July 10, 2009 at the NIH"s Clinical Center located at the main NIH campus, on 9000 Rockville Pike, Bethesda, MD. The title of Dr. Talor"s presentation is: "Multikine: Cancer Immunotherapy; how to make immunotherapy for cancer work". In the presentation, Dr. Talor will discuss Multikine"s immunotherapy clinical program for cancer, the unique mechanism of action of Multikine (published in the Journal of Clinical Oncology) and the way Multikine imparts the patient"s own immune response with the ability to mount a robust anti-tumor immune response against his/her tumor. Dr. Talor will also discuss the clinical findings from the different Multikine Phase II clinical trials which highlight the advantages that Multikine treatment provides for early disease management in newly diagnosed (treatment naive) patients with Squamous Cell Carcinoma of the Head and Neck. Early intervention in this disease is seen by many clinicians and researchers in the field as a key to improving disease outcome in these patients. Dr. Talor will also discuss the objectives of the collaborative study between the NIH, NCI under a current Material Transfer Agreement. This work is aimed at elucidating the tumor microenvironment changes, at the molecular level, brought about by Multikine treatment of head and neck cancer patients. The CEL-SCI / NIH collaborative study will use samples collected from patients with advanced primary Head and Neck cancer (Oral Squamous Cell Carcinoma) during the impending Multikine Pivotal Global Phase III trial and these samples will be tested by the NIH, NCI using Genomic Microarray technology, developed at the NIH, NCI laboratories. About CEL-SCI Corporation CEL-SCI Corporation is developing products that empower immune defenses. Its lead product is Multikine(R) which is being readied for a global Phase III trial in advanced primary head and neck cancer. CEL-SCI is also developing a vaccine to prevent and treat swine and other influenzas using its L.E.A.P.S.(TM) technology platform and expects to soon finish the validation of its state-of-the-art facility in Maryland which it expects to utilize to launch aseptic filling for stem cell produced therapies and other biological products. The Company has operations in Vienna, Virginia, and Baltimore, Maryland. When used in this report, the words "intends," "believes," "anticipated" and "expects" and similar expressions are intended to identify forward-looking statements. Such statements are subject to risks and uncertainties which could cause actual results to differ materially from those projected. Factors that could cause or contribute to such differences include, an inability to duplicate the clinical results demonstrated in clinical studies, timely development of any potential products that can be shown to be safe and effective, receiving necessary regulatory approvals, difficulties in manufacturing any of the Company"s potential products, inability to raise the necessary capital and the risk factors set forth from time to time in CEL-SCI Corporation"s SEC filings, including but not limited to its report on Form 10- K/A for the year ended September 30, 2008. The Company undertakes no obligation to publicly release the result of any revision to these forward-looking statements which may be made to reflect the events or circumstances after the date hereof or to reflect the occurrence of unanticipated events. CEL-SCI Corporation


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):

© Copyright 2009